After a stormy year in China, GlaxoSmithKline has gone through major changes including the global transfer of its oncology assets to Novartis. But the underlying broader reasons for the company's newly reported layoffs in China could be more deep-rooted and far-reaching.
After a stormy year in China, GlaxoSmithKline has gone through major changes including the global transfer of its oncology assets to Novartis. But the underlying broader reasons for the company's newly reported layoffs in China could be more deep-rooted and far-reaching.
GSK is in the process of downsizing its operations in China with plans to let go roughly 1,000 people, local...
Once-daily oral FASN inhibitor denifanstat meets all endpoints in a Chinese Phase III trial for moderate-to-severe acne, paving the way for a regulatory submission in China.
But the French major is still keen on early-stage M&A.
A study of the German biotech's intravenous complement factor C5a antibody for pyoderma gangrenosum was stopped for futility.
The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.
The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.
Wales-based group launches with $140m series A.
CEO Ben Zeskind said all options are on the table after atebimetinib showed impressive results in pancreatic cancer.
